CClinicalTrials.gg
CompletedNCT05562856Updated Oct 4, 2022

Clinical Evaluation of White Spot Lesions Treated by S-PRG Material and Composite Sealants in Comparison With ICON

An interventional study of surface pre-reacted glass filler coating material in White Spot Lesions, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jan 2020, registered Sep 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

Dental caries is the primary cause of tooth loss and oral diseases. Dental decay is a continuous pathological process with loss of tooth minerals, demineralization, which involves the destruction of tooth structure from acids. The first sign of early active demineralization is white spot lesions (WSLs) on the tooth surface, meanwhile, subsurface active mineral decomposition.

Read the detailed description

Deposition of minerals depends on the equilibrium between demineralization and remineralization which may happen as a natural repair mechanism. The aim of this trial is to comparatively evaluate the efficacy of surface pre-reacted glass filler (S-PRG) Barrier Coat coating material against the Icon resin infiltration in the ability to improve the caries lesion state of the WSLs along 1 year. Laser fluorescence was used to compare the two materials to evaluate the caries progression. PRG Barrier Coat group showed immediate significant improvement in LF scores in demineralization progress and inhibition of caries progression with a significant improved effect. S-PRG Barrier Coat was clinically successful strategy in inhibition of caries and improve remineralization.

02

Conditions studied

  • White Spot Lesions
03

In context

Lead sponsor

Al-Azhar University is the lead sponsor of 505 studies on the registry; 167 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients within 20-40 years of age.
  • Each patient has 4 or more WSLs.
  • Mild and moderate WSLs according to Gorelick's scale.
  • Good oral hygiene and willing patients who can attend the study visits.
  • a Symmetrical number of permanent teeth in each arch (mesial to second molars).

Exclusion criteria

Exclusion Criteria:

  • Active carious lesions.
  • Facial surface restorations.
  • Intrinsic and extrinsic stains.
  • Patients who have a significant medical history or if they smoke.
  • Criteria for discontinuation; Mortality and acquiring severe debilitating disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    surface pre-reacted glass filler coating material

    surface pre-reacted glass filler coating material used to remineralize WSLs

    Combination Product: surface pre-reacted glass filler coating material

  • Active comparator
    micro-invasive resin infiltration technique (Icon)

    micro-invasive resin infiltration technique (Icon) in the ability to improve caries lesion state (LF scores) and making the WSLs

    Combination Product: surface pre-reacted glass filler coating material

  • Experimental
    Permaseal resin

    Permaseal composite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs

    Combination Product: surface pre-reacted glass filler coating material

  • Experimental
    Optiguard resin

    Optiguardcomposite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs

    Combination Product: surface pre-reacted glass filler coating material

Interventions

  • Combination productsurface pre-reacted glass filler coating material

    the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs

06

What researchers measure

Primary outcomes

  1. Assessments of caries lesion state of WSLs:

    Assessing of carious lesions state of WSLs, was performed by using Diagnodent pen to record the progression or regression of caries by time. The assessment of the WSLs demineralization condition took place before intervention (baseline) \[T0\], immediately after intervention \[T1\], 3 months later \[T2\] ,6 months later \[T3\] and 1 year later \[T4\].

    Time frame: 1 year

Secondary outcomes

  1. Assessment of color change of WSLs:

    The difference in color of the WSLs were performed by Vita Easyshade V at the five distinct times: before intervention (baseline) \[T0\], immediately after intervention \[T1\], 3 months later \[T2\] ,6 months later \[T3\] and 1 year later \[T4\].

    Time frame: 1 year

07

Study locations

1 site
  • Mohamed Wakwak
    Cairo, 11768, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05562856
Lead sponsor
Al-Azhar University
Responsible party
Eslam Gabr (Assistant professor, Al-Azhar University) — Principal investigator
First posted
Oct 3, 2022
Start date
Jan 20, 2020
Primary completion
Dec 2, 2021
Completion
Dec 3, 2021
Last update
Oct 4, 2022

Study contacts

Khalid Noman, PROF
study director · Alazhar Univerisity

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion